Risk factors
Cerus (CERS) risk factors
Item 1A of every Cerus Corp. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors43 risks7 new8 dropped10 reworded
Regulatory setbacks hit European approval for the red blood cell system via CBG application closure.
Filed Mar 02, 2026 - FY2024 10-K risk factors44 risks
Cerus is commercializing the INTERCEPT Blood System amid concentration risks and stringent global healthcare regulations. The company relies heavily on third-party manufacturers, government contracts like BARDA, and achieving broader market adoption. Sustaining profitability and financing ongoing clinical developments remain central financial challenges.
Filed Feb 26, 2025